Business Context and Reporting Period
This Form 8-K Current Report, dated November 1, 2021, covers Compass Therapeutics, Inc., a Delaware corporation. The filing reports the entry into a material definitive agreement for a public offering of common stock and the commencement of trading on the Nasdaq Capital Market.
Key Financial Metrics
The filing details a capital raise rather than operational financial performance. Key metrics include:
- Shares Offered: 35,715,000 shares of Common Stock.
- Offering Price: $3.50 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 5,357,250 additional shares.
- Expected Net Proceeds: Approximately $117.3 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Liquidity Impact: The transaction is expected to significantly increase the company's cash position upon closing.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of an underwriting agreement with SVB Leerink LLC, as representative of the underwriters. Additionally, the Company's Common Stock commenced trading on the Nasdaq Capital Market on November 2, 2021, representing an uplisting from its previous trading venue.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Offering is expected to close on November 4, 2021. The Company intends to use the net proceeds for general corporate purposes, though specific allocation details are not provided in this excerpt.
Risks and Contingencies: The Company and its officers, directors, and certain stockholders have agreed to a 90-day lock-up period following the date of the Prospectus Supplement, during which they cannot offer, sell, or transfer shares of Common Stock, subject to certain exceptions. The Company has agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected November 4, 2021) and the actual net proceeds received.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 5,357,250 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific terms regarding indemnification and covenants.
- Check subsequent filings for the specific allocation of the approximately $117.3 million in net proceeds.
- Monitor the 90-day lock-up expiration date for potential increases in share supply.